Selected scientific papers
This section contains a selection of Dr. Breggin's scientific articles spanning 1964 to the present. They can be arranged chronologically in order to facilitate an overview of his work over the years.
 
 

DocumentsDate added

Order by : Name | Date | Hits [ Descendent ]
file icon Paxil Special Report I: Court filing makes suppressed Paxil data public ('06) 03/01/2006
"Court Filing Makes Public My Previously Suppressed Analysis of Paxil's Effects." Ethical Human Psychology and Psychiatry, 8, 77-84, 2006.
file icon Paxil Special Report II: How GSK suppressed Paxil data (2006) 04/01/2006
"How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence", Ethical Human Psychology and Psychiatry, 8, 91-100, 2006.
file icon Paxil Special Report III: Drug Company Suppressed Data on Paxil (2006) 05/01/2006
"Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide", Ethical Human Psychology and Psychiatry, 8, 255-263, 2006.
file icon Politics, practice, and breaking news (2006) 02/01/2006
"Politics, Practice, and Breaking News." Ethical Human Psychology and Psychiatry, 8, 3-6, 2006.
file icon Precious the crow (1987) 01/01/1987
"Precious the Crow." Voices (Journal of the American Academy of Psychotherapists) 23:32-42, Summer, 1987.
file icon Psychiatric drug-induced Chronic Brain Impairment (CBI) 01/25/2012
Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for longterm treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23: 193-200.
Peter R. Breggin, MD
Abstract: Understanding the hazards associated with long-term exposure to psychiatric drugs is very important but rarely emphasized in the scientific literature and clinical practice. Drawing on the scientific literature and clinical experience, the author describes the syndrome of Chronic Brain Impairment (CBM) which can be caused by any trauma to the brain including Traumatic Brain Injury (TBI), electroconvulsive therapy (ECT), and long-term exposure to psychiatric medications. Knowledge of the syndrome should enable clinicians to more easily identify long-term adverse effects caused by psychiatric drugs while enabling researchers to approach the problem with a more comprehensive understanding of the common elements of brain injury as they are manifested after long-term exposure to psychiatric medications. Treatment options are also discussed.
file icon Psychiatry's reliance on coercion (1999) 02/01/1999
"Psychiatry's Reliance on Coercion." Ethical Human Sciences and Services, 1:115-118, 1999.
file icon Psychiatry's role in the holocaust (1993) 01/01/1993
"Psychiatry's Role in the Holocaust." International Journal of Risk and Safety in Medicine 4:133-148, 1993. Adapted from a paper delivered at "Medical Science Without Compassion" in Cologne, Germany and published in the conference proceedings.
file icon Psychopharmacology and human values (2003) 01/01/2003
"Psychopharmacology and Human Values." Journal of Humanistic Psychology, 43: 34-49, 2003.
file icon Psychostimulants in the treatment of children diagnosed with ADHD (1999) 06/01/1999
"Psychostimulants in the Treatment of Children Diagnosed with ADHD: Risks and Mechanism of Action." International Journal of Risk and Safety in Medicine, 12 (1), 3-35, 1999.
<< Start < Prev 1 2 3 4 5 6 7 Next > End >>
Results 31 - 40 of 66

 

WARNING!

Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families.